Dr Robin Brown


Medicines Discovery Catapult

Robin was appointed Chairman of the Medicines Discovery Catapult in July 2018.

Most recently he was the Chief Executive Officer of KWS BioTest, a specialist immunology-based contract research organisation. In January 2018 KWS was acquired by Charles River Laboratories. Immediately before joining KWS, Robin spent eight years as a venture partner at Advent Healthcare Ventures (US) and was responsible for the scientific direction and corporate governance of a number of companies within the investment portfolios.

Prior to this he was the Chief Scientific Officer of Devgen (acquired by Syngenta) and Galapagos NV. Dr Brown also spent nine years at GSK, latterly as Head of Cell Biology and as an academic gained his PhD in the laboratory of Professor Alan Hall at the Institute of Cancer Research, London. He undertook postdoctoral work in the United States (Harvard) and London (Ludwig Institute).